JRCT ID: jRCT2080222464
Registered date:18/04/2014
Basic Information
Recruitment status | |
---|---|
Health condition(s) or Problem(s) studied | Patients with malignant soft tissue sarcomas of histological types that have been reported to carry chromosomal translocations |
Date of first enrollment | 18/04/2014 |
Target sample size | 50 |
Countries of recruitment | |
Study type | Interventional |
Intervention(s) | investigational material(s) Generic name etc : ET-743 INN of investigational material : trabectedin Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational material : ET-743 (initial dose 1.2 mg/m2) will be administered via a central venous line in 24 hours. Treatment cycle consists of 21 days. |
Outcome(s)
Primary Outcome | Safety CTCAE ver.4.03 |
---|---|
Secondary Outcome | Overall response rate, Disease control rate, Progression free survival RECIST ver.1.1 |
Key inclusion & exclusion criteria
Age minimum | >= 19age old |
---|---|
Age maximum | Not applicable |
Gender | Both |
Include criteria | Any of translocation-related sarcomas histopathologically confirmed at the study site Unresponsiveness or intolerability to the standard chemotherapy regimens Other |
Exclude criteria | Severe concurrent disease Other |
Related Information
Primary Sponsor | Taiho Pharmaceutical Co., Ltd. |
---|---|
Secondary Sponsor | |
Source(s) of Monetary Support | Taiho Pharmaceutical Co., Ltd. |
Secondary ID(s) | JapicCTI-142514 |
Contact
Public contact | |
Name | |
Address | toiawase@taiho.co.jp |
Telephone | |
Affiliation | Taiho Pharmaceutical Co., Ltd. |
Scientific contact | |
Name | |
Address | toiawaseCD1@taiho.co.jp |
Telephone | |
Affiliation | Taiho Pharmaceutical Co., Ltd. |